‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend
From the article
Jim Cramer stared down a stock yielding 7% and sitting near its 52-week low, and still would not tell viewers to buy it. On the July 7 episode of CNBC’s Mad Money, a caller from Orland Park, Illinois pitched Pfizer as an income-and-value setup, and Cramer conceded the case looked tempting. He landed on a ... ‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend
Continue reading on 24/7 Wall St.You might also wanna read
Mad Money 07/07/26 | Audio Only
Whatfinger·1d ago
Jim Cramer turns cautious on stocks as bull market pillars weaken
CNBC's Jim Cramer has turned significantly more cautious on stocks, stating he is "not that bullish" and advising investors to wait for a be
cnbc.com·1mo agoJim Cramer turns cautious on stocks as bull market pillars weaken
CNBC's Jim Cramer has turned significantly more cautious on stocks, stating he is "not that bullish" and advising investors to wait for a be
cnbc.com·1mo agoOpinion: Pfizer's Dividend Is Riskier Than You Might Think
Bars·2d ago
Mad Money 07/08/26 | Audio Only
Whatfinger·20h ago
Jim Cramer identifies 5 bargain stocks to buy amid market rotation following June jobs report
CNBC's Jim Cramer advises investors not to fear the current market rotation, but instead view it as a buying opportunity for high-quality st
cnbc.com·2d agoJim Cramer Warns Wave of IPOs and Bond Sales, Not Iran Tensions, Poses Bigger Threat to Stock Market Rally
Tekedia·8h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.